Alunbrig FDA Approval History
FDA Approved: Yes (First approved April 28, 2017)
Brand name: Alunbrig
Generic name: brigatinib
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: Non-Small Cell Lung Cancer
Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Development Timeline for Alunbrig
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.